The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Angina Pectoris Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work.
The global Angina Pectoris Drugs market size is expected to reach US$ 12530 million by 2029, growing at a CAGR of 5.4% from 2023 to 2029. The market is mainly driven by the significant applications of Angina Pectoris Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and ASCs,, are propelling Angina Pectoris Drugs market. Beta Blockers, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Calcium Antagonists segment is estimated at % CAGR for the next seven-year period.
Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Angina Pectoris Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Angina Pectoris Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Angina Pectoris Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Angina Pectoris Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Angina Pectoris Drugs covered in this report include Pfizer, Bayer, AstraZeneca, Gilead, Novartis, GlaxoSmithKline, Merck, Mylan and Teva Pharmaceutical, etc.
The global Angina Pectoris Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Bayer
AstraZeneca
Gilead
Novartis
GlaxoSmithKline
Merck
Mylan
Teva Pharmaceutical
Global Angina Pectoris Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Angina Pectoris Drugs market, Segment by Type:
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others
Global Angina Pectoris Drugs market, by Application
Hospitals
Clinics
ASCs
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Angina Pectoris Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Angina pectoris is a clinical indication characterized by precordial heaviness or discomfort due to transient myocardial ischemia without infarction, elicited by physical exertion or psychological stress. Angina pectoris is categorized as - stable, unstable, microvascular and Prinzmetal / variant. Angina pectoris is an initial presentation of coronary heart disease (CHD) and exerts a major impact on quality of life (QOL), costs to the society and ability to work.
The global Angina Pectoris Drugs market size is expected to reach US$ 12530 million by 2029, growing at a CAGR of 5.4% from 2023 to 2029. The market is mainly driven by the significant applications of Angina Pectoris Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and ASCs,, are propelling Angina Pectoris Drugs market. Beta Blockers, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Calcium Antagonists segment is estimated at % CAGR for the next seven-year period.
Chronic stable angina pectoris has a prevalence of 2.0 - 4.0% in the seven major markets (U.S., U.K., Germany, France, Italy, Spain, Japan). Heart Disease and Stroke Statistics from American Heart Association estimates indicate that over nine million adults in the U.S. have chronic angina pectoris.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Angina Pectoris Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Angina Pectoris Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Angina Pectoris Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Angina Pectoris Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Angina Pectoris Drugs covered in this report include Pfizer, Bayer, AstraZeneca, Gilead, Novartis, GlaxoSmithKline, Merck, Mylan and Teva Pharmaceutical, etc.
The global Angina Pectoris Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Bayer
AstraZeneca
Gilead
Novartis
GlaxoSmithKline
Merck
Mylan
Teva Pharmaceutical
Global Angina Pectoris Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Angina Pectoris Drugs market, Segment by Type:
Beta Blockers
Calcium Antagonists
Anticoagulants
Anti-Platelets
Others
Global Angina Pectoris Drugs market, by Application
Hospitals
Clinics
ASCs
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Angina Pectoris Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Angina Pectoris Drugs
1.1 Angina Pectoris Drugs Market Overview
1.1.1 Angina Pectoris Drugs Product Scope
1.1.2 Angina Pectoris Drugs Market Status and Outlook
1.2 Global Angina Pectoris Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Angina Pectoris Drugs Market Size by Region (2018-2029)
1.4 Global Angina Pectoris Drugs Historic Market Size by Region (2018-2023)
1.5 Global Angina Pectoris Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Angina Pectoris Drugs Market Size (2018-2029)
1.6.1 North America Angina Pectoris Drugs Market Size (2018-2029)
1.6.2 Europe Angina Pectoris Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Angina Pectoris Drugs Market Size (2018-2029)
1.6.4 Latin America Angina Pectoris Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Angina Pectoris Drugs Market Size (2018-2029)
2 Angina Pectoris Drugs Market by Type
2.1 Introduction
2.1.1 Beta Blockers
2.1.2 Calcium Antagonists
2.1.3 Anticoagulants
2.1.4 Anti-Platelets
2.1.5 Others
2.2 Global Angina Pectoris Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Angina Pectoris Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Angina Pectoris Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Angina Pectoris Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Angina Pectoris Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Angina Pectoris Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Angina Pectoris Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Angina Pectoris Drugs Revenue Breakdown by Type (2018-2029)
3 Angina Pectoris Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 ASCs
3.2 Global Angina Pectoris Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Angina Pectoris Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Angina Pectoris Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Angina Pectoris Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Angina Pectoris Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Angina Pectoris Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Angina Pectoris Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Angina Pectoris Drugs Revenue Breakdown by Application (2018-2029)
4 Angina Pectoris Drugs Competition Analysis by Players
4.1 Global Angina Pectoris Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Angina Pectoris Drugs as of 2022)
4.3 Date of Key Players Enter into Angina Pectoris Drugs Market
4.4 Global Top Players Angina Pectoris Drugs Headquarters and Area Served
4.5 Key Players Angina Pectoris Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Angina Pectoris Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Angina Pectoris Drugs Products, Services and Solutions
5.1.4 Pfizer Angina Pectoris Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Bayer
5.2.1 Bayer Profile
5.2.2 Bayer Main Business
5.2.3 Bayer Angina Pectoris Drugs Products, Services and Solutions
5.2.4 Bayer Angina Pectoris Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Bayer Recent Developments
5.3 AstraZeneca
5.3.1 AstraZeneca Profile
5.3.2 AstraZeneca Main Business
5.3.3 AstraZeneca Angina Pectoris Drugs Products, Services and Solutions
5.3.4 AstraZeneca Angina Pectoris Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Gilead Recent Developments
5.4 Gilead
5.4.1 Gilead Profile
5.4.2 Gilead Main Business
5.4.3 Gilead Angina Pectoris Drugs Products, Services and Solutions
5.4.4 Gilead Angina Pectoris Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Gilead Recent Developments
5.5 Novartis
5.5.1 Novartis Profile
5.5.2 Novartis Main Business
5.5.3 Novartis Angina Pectoris Drugs Products, Services and Solutions
5.5.4 Novartis Angina Pectoris Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Novartis Recent Developments
5.6 GlaxoSmithKline
5.6.1 GlaxoSmithKline Profile
5.6.2 GlaxoSmithKline Main Business
5.6.3 GlaxoSmithKline Angina Pectoris Drugs Products, Services and Solutions
5.6.4 GlaxoSmithKline Angina Pectoris Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 GlaxoSmithKline Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Angina Pectoris Drugs Products, Services and Solutions
5.7.4 Merck Angina Pectoris Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Merck Recent Developments
5.8 Mylan
5.8.1 Mylan Profile
5.8.2 Mylan Main Business
5.8.3 Mylan Angina Pectoris Drugs Products, Services and Solutions
5.8.4 Mylan Angina Pectoris Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Mylan Recent Developments
5.9 Teva Pharmaceutical
5.9.1 Teva Pharmaceutical Profile
5.9.2 Teva Pharmaceutical Main Business
5.9.3 Teva Pharmaceutical Angina Pectoris Drugs Products, Services and Solutions
5.9.4 Teva Pharmaceutical Angina Pectoris Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Teva Pharmaceutical Recent Developments
6 North America
6.1 North America Angina Pectoris Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Angina Pectoris Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Angina Pectoris Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Angina Pectoris Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Angina Pectoris Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Angina Pectoris Drugs Market Dynamics
11.1 Angina Pectoris Drugs Industry Trends
11.2 Angina Pectoris Drugs Market Drivers
11.3 Angina Pectoris Drugs Market Challenges
11.4 Angina Pectoris Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
